IP Library › Granted Patent US 12,433,920
Granted Patent B2
US 12,433,920 · App. 14/781,270 · Granted Oct 7, 2025

C. novyi for the treatment of solid tumors in non-human animals

Inventors: Saurabh Saha (Wellesley Hills, MA); Shibin Zhou (Owings Mills, MD); Bert Vogelstein (Baltimore, MD); Kenneth W. Kinzler (Bel Air, MD)
Assignee: Biomed Valley Discoveries, Inc.
A61K35/74A61K31/65A61K45/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,433,920
App. No.
14/781,270
Granted
Oct 7, 2025
Kind
B2
Abstract

The present invention provides, inter alia, methods for treating or ameliorating an effect of a solid tumor present in a non-human animal. These methods include administering intratumorally to the non-human animal a unit dose of C. novyi , preferably C. novyi NT, colony forming units (CFUs), which contains about 1×106-1×1010 CFUs suspended in a pharmaceutically acceptable carrier or solution. Methods for debulking a solid tumor present in a non-human animal, a method for microscopically precise excision of tumor cells in a non-human animal, methods for treating or ameliorating an effect of a solid tumor that has metastasized to one or more sites in a non-human animal, methods for ablating a solid tumor present in a non-human animal, unit doses of C. novyi , preferably C. novyi NT, CFUs, and kits for treating or ameliorating an effect of a solid tumor present in a non-human animal are also provided.

Claims (39)

1. A method for debulking a solid tumor present in a non-human animal comprising administering intratumorally to the non-human animal a plurality of treatment cycles of a unit dose of C. novyi colony forming units (CFUs) comprising 1×10 6 -1×10 10 CFUs suspended in a pharmaceutically acceptable carrier or solution, wherein the C. novyi is the only administered anti-tumor treatment, and wherein the solid tumor is a mast cell tumor.

2. The method according to claim 1 , wherein the unit dose comprises from 1×10 7 -1×10 8 C. novyi CFUs.

3. The method according to claim 1 , wherein the unit dose comprises 1×10 8 C. novyi CFUs.

4. The method according to claim 1 , wherein the C. novyi CFUs are selected from the group consisting of vegetative and spore forms.

5. The method according to claim 1 , wherein the C. novyi is C. novyi NT.

6. The method according to claim 5 , wherein the unit dose comprises 1×10 6 -1×10 10 C. novyi NT spores.

7. The method according to claim 5 , wherein the unit dose comprises from 1×10 7 -1×10 8 C. novyi NT spores.

8. The method according to claim 5 , wherein the unit dose comprises 1×10 8 C. novyi NT spores.

9. The method according to claim 1 , wherein the administering step comprises injecting the unit dose at a single location into the tumor.

10. The method according to claim 1 , wherein the administering step comprises injecting the unit dose at multiple unique locations into the tumor.

11. The method according to claim 1 , wherein the administering step comprises injecting the unit dose at 1-5 unique locations into the tumor.

12. The method according to claim 1 , wherein the administering step comprises injecting the unit dose at 5 or more unique locations into the tumor.

13. The method according to claim 1 , wherein 2-10 treatment cycles are administered.

14. The method according to claim 1 , wherein 2-4 treatment cycles are administered.

15. The method according to claim 1 , wherein an interval between each treatment cycle is about 5-100 days.

16. The method according to claim 1 , wherein an interval between each treatment cycle is about 7 days.

17. The method according to claim 6 further comprising administering IV fluids to the non-human animal before, during, and/or after each administration of the C. novyi NT spores.

18. The method according to claim 6 , wherein 2-4 treatment cycles are administered.

19. The method according to claim 1 further comprising administering IV fluids to the non-human animal before, during, and/or after each administration of the C. novyi CFUs.

20. The method according to claim 1 further comprising providing the non-human animal with a first course of antibiotics for a period of time and at a dosage that is effective to treat or alleviate an adverse side effect selected from the group consisting of infections, vomiting, hematochezia, fever, and combinations thereof caused by the C. novyi CFUs.

21. The method according to claim 20 , wherein the antibiotics are administered for two weeks post C. novyi administration.

22. The method according to claim 20 , wherein the antibiotics are selected from the group consisting of amoxicillin, clavulanate, metronidazole, and combinations thereof.

23. The method according to claim 20 further comprising providing the non-human animal with a second course of antibiotics for a period of time and at a dosage that is effective to treat or alleviate an adverse side effect selected from the group consisting of infections, vomiting, hematochezia, fever, and combinations thereof caused by the C. novyi.

24. The method according to claim 23 , wherein the second course of antibiotics is initiated after completion of the first course of antibiotics and is carried out for 1-6 months.

25. The method according to claim 23 , wherein the second course of antibiotics is initiated after completion of the first course of antibiotics and is carried out for 3 months.

26. The method according to claim 23 , wherein the antibiotic used in the second course is doxycycline.

27. The method according to claim 1 , wherein the solid tumor is resistant to a therapy selected from the group consisting of chemotherapy, radiation therapy, immunotherapy, and combinations thereof.

28. The method according to claim 1 , wherein the solid tumor is refractory to standard therapy or the solid tumor is without an available standard therapy.

29. The method according to claim 1 , wherein the unit dose of C. novyi induces a potent localized inflammatory response and an adaptive immune response in the non-human animal.

30. The method according to claim 1 , wherein the non-human animal is selected from the group consisting of domesticated animals and farm animals.

31. The method according to claim 30 , wherein the domesticated animals are selected from the group consisting of dogs, cats, and horses.

32. The method according to claim 30 , wherein the domesticated animal is a dog.

33. The method according to claim 30 , wherein the farm animals are selected from the group consisting of sheep, pigs, and cattle.

34. A method for debulking a solid tumor that has metastasized to one or more sites in a non-human animal comprising administering intratumorally to the non-human animal a plurality of treatment cycles of a unit dose of C. novyi NT colony forming units (CFUs) comprising 1×10 6 -1×10 10 CFUs suspended in a pharmaceutically acceptable carrier or solution, wherein the C. novyi is the only administered anti-tumor treatment, and wherein the solid tumor is a mast cell tumor.

35. The method according to claim 34 , wherein at least one site is distal to the original solid tumor.

36. A method for debulking a solid tumor present in a non-human animal comprising administering intratumorally to the non-human animal a plurality of treatment cycles of a unit dose of C. novyi NT spores comprising 1×10 8 spores per cycle, each unit dose of C. novyi NT being suspended in a pharmaceutically acceptable carrier or solution, wherein the C. novyi is the only administered anti-tumor treatment, and wherein the solid tumor is a mast cell tumor.

37. A method for treating or ameliorating an effect of a mast cell tumor present in a dog comprising administering a plurality of treatment cycles of a unit dose of C. novyi NT spores, each treatment cycle comprising injecting one unit dose of 1×10 8 C. novyi NT spores into the mast cell tumor, each unit dose of C. novyi NT being suspended in a pharmaceutically acceptable carrier or solution, and wherein the C. novyi NT is the only administered anti-tumor treatment.

38. A method for ablating a solid tumor present in a non-human animal comprising administering intratumorally to the non-human animal a plurality of treatment cycles of a unit dose of C. novyi CFUs comprising 1×10 6 -1×10 10 CFUs suspended in a pharmaceutically acceptable carrier or solution, wherein the tumor is ablated leaving a margin of normal tissue, wherein the C. novyi is the only administered anti-tumor treatment, and wherein the solid tumor is a mast cell tumor.

39. The method according to claim 38 , wherein the non-human animal is a dog.

Assignments (2)
CONFIRMATORY LICENSE Recorded Aug 24, 2020
From: THE JOHNS HOPKINS UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR
Reel/Frame 053575/0152 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 28, 2016
From: SAHA, SAURABH
To: BIOMED VALLEY DISCOVERIES, INC.
Reel/Frame 037610/0050 →
Continuity (2)
Provisional Application 61806484 · Mar 29, 2013
Related Publication 20160045556A1 · Feb 18, 2016
References Cited (44)
US 7344710B2 · Dang et al. · 2008 [cited by applicant]
US 20050079157A1 · Dang · 2005 [cited by examiner]
US 20100034814A1 · Sabbadini · 2010 [cited by examiner]
EP 1675465B1 · 2010 [cited by applicant]
WO 2005018332A1 · 2005 [cited by applicant]
Kim et al., Atypical radiological features of a leiomyosarcoma that arose from the ovarian vein and mimicked a vascular tumor, The British Journal of Radiology, 83 (2010), e95-e97. [cited by examiner]
Dunn et al., Disseminated Osteomyelitis Caused by Clostridium novyi in a Cat, Case Report, Can Vet J, 24 (1983) 312-315. [cited by examiner]
OB-GYN 101 Pharmacy, Antibiotics of Choice, Available Online at: www.brooksidepress.org/ Products/OBGYN_101/MyDocuments4/Pharmacy/AntibioticsofChoice.htm, at least as early as Dec. 18, 2005 per Internet Archive Wayback … [cited by examiner]
Korman et al., Checkpoint Blockade in Cancer Immunotherapy, Adv Immunol, 90 (2006), 297-339. [cited by examiner]
Agrawal, N. et al. Bacteriolytic therapy can generate a potent immune response against experimental tumors. Proc Natl Acad Sci U S A 101, 15172-7 (2004). [cited by applicant]
Bai, R.Y., et al. V. Antiparasitic mebendazole shows survival benefit in 2 preclinical models of glioblastoma multiforme. Neuro-oncology 13, 974-982 (2011). [cited by applicant]
Barretina, J., et al. Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nature genetics 42,715-721 (2010). [cited by applicant]
Bettegowda, C., et al. The genome and transcriptomes of the anti-tumor agent Clostridium novyi-NT. Nature biotechnology 24, 1573-1580 (2006). [cited by applicant]
Bettegowda, C., & Saha, S. Clostridium novyi-NT Cancer Therapeutic. Chordoma Foundation. Mar. 22, 2013. [cited by applicant]
Bettegowda, C., et al. Overcoming the hypoxic barrier to radiation therapy with anaerobic bacteria. Proc Natl Acad Sci U S A. Dec. 9, 2003; 100(25): 15083-15088. [cited by applicant]
Breed, Robert S.; Dotterrer, W. D. “The Number of Colonies Allowable on Satisfactory Agar Plates”. Journal of Bacteriology 1 (3): 321-331 (1916). [cited by applicant]
Brook, I. Anaerobic infections in children. Microbes Infect. Oct. 2002;4(12):1271-80. [cited by applicant]
Carey, R.W., et al. Clostridial oncolysis in man. Eur. J. Cancer 3, 37-46 (1967). [cited by applicant]
Chmielecki, J., et al. Whole-exome sequencing identifies a recurrent NAB2-STAT6 fusion in solitary fibrous tumors. Nature genetics 45, 131-132 (2013). [cited by applicant]
Dang, L.H. et al. Targeting Vascular and Avascular Compartments of Tumors with C. novyi-NT and Anti-Microtubule Agents. Cancer Biol Ther 3, 326-37 (2004). [cited by applicant]
Dang, L.H., et al., “Combination bacteriolytic therapy for the treatment of experimental tumors.” PNAS. vol. 98, pp. 15155-15160 (2001). [cited by applicant]
Diaz, L.A., Jr. et al. Pharmacologic and toxicologic evaluation of C. novyi-NT spores. Toxicol Sci 88, 562-75 (2005). [cited by applicant]
European Medicines Agency. Combined VeDDRA list of clinical terms for reporting suspected adverse reactions in animals and humans to veterinary medicinal products (2012). [cited by applicant]
Gavhane, Y.N. et al., “Solid Tumors: Facts, Challenges and Solutions.” International J. of Pharma Science and Research, vol. 2, pp. 1-12 (2011). [cited by applicant]
International Search Report for PCT/US2014/032224, mailed Nov. 20, 2014. [cited by applicant]
Jain, R.K. & Forbes, N.S. Can engineered bacteria help control cancer? Proc Natl Acad Sci U S A 98, 14748-50 (2001). [cited by applicant]
Jones, S., et al. Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science 330, 228-231 (2010). [cited by applicant]
Joseph, C., et al. Exomic Analysis of myxoid liposarcomas, synovial sarcomas and osteosarcomas. Genes Chromosomes Cancer. Jan. 2014;53(1):15-24. [cited by applicant]
Lee, R.S., et al. A remarkably simple genome underlies highly malignant pediatric rhabdoid cancers. J Clin Invest. Aug. 2012;122(8):2983-8. [cited by applicant]
Leu, KM, et al. Laboratory and clinical evidence of synergistic cytotoxicity of sequential treatment with gemcitabine followed by docetaxel in the treatment of sarcoma. J Clin Oncol. May 1, 2004;22(9):1706-12. [cited by applicant]
Nemunaitis, J, et al. Pilot trial of genetically modified, attenuated [cited by applicant]
Nicolson, GL & Nicolson, NL. Gulf War illnesses: complex medical, scientific and political paradox. Med Confl Surviv. Apr.-Jun. 1998;14(2):156-65. [cited by applicant]
Paoloni, M., et al. Translation of new cancer treatments from pet dogs to humans. Nature Reviews Cancer 8, 147-156 (2008). [cited by applicant]
Parker, R.C., Plummer, H.C., Siebenmann, C.O. & Chapman, M.G. Effect of histolyticus infection and toxin on transplantable mouse tumors. Proc. Soc. Exp. Biol. Med. 66, 461 (1947). [cited by applicant]
Patnaik, A.K., et al. Canine cutaneous mast cell tumor: morphologic grading and survival time in 83 dogs. Veterinary pathology 21, 469-474 (1984). [cited by applicant]
Roberts, N.J., et al. Intratumoral injection of Clostridium novyi-NT spores induces antitumor responses. Sci Transl Med. Aug. 13, 2014;6(249):249ra111. [cited by applicant]
Sabattini, S., et al. Histologic Grading of Canine Mast Cell Tumor: Is 2 Better Than 3? Vet Pathol. Jan. 2015;52(1):70-3. [cited by applicant]
Schlom, J. Recent advances in therapeutic cancer vaccines. Cancer Biother Radiopharm. Feb. 2012;27(1):2-5. [cited by applicant]
Smedley, R.C., et al. Prognostic markers for canine melanocytic neoplasms: a comparative review of the literature and goals for future investigation. Veterinary pathology 48, 54-72 (2011). [cited by applicant]
Vail, D.M., et al. Spontaneously occurring tumors of companion animals as models for human cancer. Cancer investigation 18, 781-792 (2000). [cited by applicant]
Van Mellaert, L, et al. Clostridium spores as anti-tumour agents. Trends Microbiol. Apr. 2006;14(4):190-6. [cited by applicant]
Veterinary Co-Operative Oncology Group. Veterinary Co-operative Oncology Group—Common Terminology Criteria for Adverse Events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.… [cited by applicant]
Vogelstein, B., et al. Cancer genome landscapes. Science 339, 1546-1558 (2013). [cited by applicant]
Walther, W., et al. Novel jet-injection technology for nonviral intratumoral gene transfer in patients with melanoma and breast cancer. Clin Cancer Res. Nov. 15, 2008;14(22):7545-53. [cited by applicant]